- Tezspire met all main and secondary objectives in a Phase 3 eosinophilic esophagitis study, with benefits sustained through one year.
- An eosinophilic esophagitis approval would give Tezspire a third indication and position it against Sanofi and Regeneron's Dupixent.
- Courts in Maryland and Washington, D.C., rejected separate AstraZeneca and Merck lawsuits challenging the Medicare drug-price negotiation program.
Quotes
“statistically significant and clinically meaningful improvements”
“support an attractive third indication for Tezspire with blockbuster potential”
Sources
- New data could widen use of AstraZeneca, Amgen immune disease drugBioPharma Dive
- <a href="https://www.fiercepharma.com/pharma/amgen-az-tezspire-phase-3-eosinophilic-esophagitis-turning-heat-dupixent" hreflang="en">Amgen, AZ’s Tezspire lands phase 3 eosinophilic esophagitis win, turning up heat on Dupixent</a>FiercePharma